CD19 and leukemia: FITC-CAR T cells have been redirected against tumours using anti-CD19 or anti-CD20 antibodies coupled to FITC55,56, but these antigens are expressed on only a subset of leukaemias and lymphomas, and we already have effective CAR T cell products approved in this setting.